Hereditary antithrombin deficiency: heterogeneity of the molecular basis and mortality in Dutch families

• Published in: Blood 1994-12, Vol.84 (12), p.4209-4213
• Main Authors: van Boven, H H, Olds, R J, Thein, S L, Reitsma, P H, Lane, D A, Briët, E, Vandenbroucke, J P, Rosendaal, F R
• Format: Article
• Language: English
• Subjects: Antithrombin III - genetics; Antithrombin III Deficiency; Base Sequence; Female; Genetic Diseases, Inborn - genetics; Genetic Diseases, Inborn - mortality; Heterozygote; Humans; Male; Molecular Sequence Data; Netherlands - epidemiology; Point Mutation; Sequence Deletion; Terminator Regions, Genetic
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.v84.12.4209.bloodjournal84124209

We studied the molecular basis and genetic heterogeneity of hereditary antithrombin (III) deficiency in nine Dutch families. Polymerase chain reaction (PCR) amplification and direct sequencing of all antithrombin gene exons and flanking intronic regions identified mutations in eight families. Given the opportunity to correlate the molecular basis with survival, we addressed the relevance of molecular defects to mortality in inherited antithrombin deficiency. The defects included single nucleotide deletions (7671 del G, 7768-69 del G) and insertions (5501 ins A, 2463 G-->TC) that lead to frameshifts, a single base substitution [5381 C-->T (129Arg-->stop)] leading to a premature termination codon, and single base substitutions resulting in amino acid substitutions [2652 A-->C (63Tyr-->Ser), 13380 T-->C (421Ile-->Thr), and 13407 G-->T (430Cys-->Phe)]. All affected individuals were heterozygous for the defects. Previously we found in Dutch families that antithrombin deficiency did not lead to higher mortality compared with the general population. In accordance with these findings, we observed no excess mortality in the nine families [Observed:Expected, 52:52.6; standardised mortality ratio (SMR) 1.0, 95% confidence interval (CI), 0.7-1.3]. Our findings confirmed a considerable genetic heterogeneity underlying antithrombin deficiency. We therefore concluded that the lack of excess mortality in these families is not caused by a Dutch mild defect. We suggest that the longevity is not affected by molecular defects in the antithrombin gene and hypothesize that differences in mortality or natural history between families most likely result from other (genetic) risk factors.